GLP-1 medications work through several complementary mechanisms
Such ratio significantly increased from baseline after 26 weeks of treatment with liraglutide 1.8 mg/day, indicating a reduction in liver steatosis, whereas it was unchanged in patients treated with lower doses of liraglutide, glimepiride or placebo
Some regulators treat it as a complex generic, especially if chemically synthesised, while others lean toward biosimilar frameworks
GLP-1 agonist oral formulations are significantly less expensive than injectable forms
NAC's primary efficacy is shown when it is needed to regenerate glutathione after overdoses of certain NSAIDs like aspirin or acetaminophen which may lead to a depletion of liver glutathione stores
As a compounding pharmacist, I find this encouraging because it shows there's active discussion around therapies that many patients and providers have been asking about